STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #773 by analyst upside · 2026-06-27
BIOA
BioAge Labs, Inc.
Healthcare · Market Cap $1B · P/E 0x
ANALYST PRICE TARGET
+108.3%
implied upside to consensus target
Current Price $23.76
Consensus Target $49.5
Bull Target $73.0
Bear Target $23.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
3
Hold
2
Sell
1
52-Week Low $4.07
52-Week High $24.93
YTD Return +85.2%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) N/A
Forward P/E -11.5x
EPS (TTM) $-2.40
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $10M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $4.07
52-Week High $24.93
Current Price $23.76
Bear Target $23.0
Bull Target $73.0
● Now $23.76 ● Target $49.5
TRADING DATA
Avg Volume 446K
YTD Return +85.2%
Analyst Count 8
Consensus Buy
Upside to Target +108.3%
Last Updated 2026-06-27

ANALYST SUMMARY

BioAge Labs, Inc. (BIOA) is currently trading at $23.76 with a Wall Street consensus price target of $49.5, implying potential upside of 108.3% over the next 12 months. 8 analysts currently cover BIOA, with a consensus rating of Buy - 62% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $73.0, while the most cautious has a target of $23.0.

BIOA operates in the Healthcare sector with a market capitalisation of $1B. The stock is up 85.2% year-to-date and is currently trading near the upper end of its 52-week range of $4.07 – $24.93.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for BIOA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Roth Capital ● Initiated
Buy 2026-05-27 Building track record
BTIG ● Initiated
Buy 2026-05-13 38% win rate (8 calls)
Needham ● Initiated
Buy 2026-03-27 20% win rate (5 calls)
Citigroup — Reiterated
Buy → Buy 2026-03-10 Building track record
Oppenheimer ● Initiated
Outperform 2026-02-25 14% win rate (7 calls)
Jefferies ↑ Upgrade
Hold → Buy 2026-02-18 50% win rate (6 calls)
Piper Sandler ● Initiated
Overweight 2026-01-27 14% win rate (7 calls)
Morgan Stanley ↑ Upgrade
Underweight → Equal-Weight 2025-12-08 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
31
out of 100
Coverage depth
17/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →